Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2157)	1/16/2008 1:09:59 PM
From: Jibacoa	Respond to of 3722

O.T. Well, in spite of INTC, C & JPM bad news, the DOW has been trying to stay on positive territory today.<g> Apparently with the help of the green back getting a little stronger & gold futures for Feb delivery tumbling $22.1 (2.5%), to $880.5 in NY The dollar index rose for the first time in 5 days, up 1% at 76.3 after better-than-expected U.S. output data. But things still don't look too good. When the market is going down, any short spikes in midweek are suspect & don't avoid the possibility of blue or black Mondays. It seems better to still keep the power dry.<g> Bernard

To: Jibacoa who wrote (2157)	1/30/2008 4:30:31 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ARWR was up for 3rd day on a roll. It was up a modest 3.53% on volume of 201,568 > its ADV. bigcharts.marketwatch.com It announced on Monday the appointment of Dr. Mauro Ferrari to its Board of Scientific Strategy. Dr.Ferrari is one of the most well-known experts in leveraging nanotechnology to treat and diagnose cancer. He said that ARWR "is in a unique position to develop and bring to the clinic new approaches and products that will revolutionize healthcare.” Dr.Ferrari serves in a number of academic roles, including President of the Alliance for NanoHealth in Houston, TX; Professor & Director of the Center for NanoMedicine, Brown Foundation Institute of Molecular Medicine; Chairman of the Department of Biomedical Engineering at the University of Texas Health Science Center at Houston; Professor of Experimental Therapeutics at the University of Texas M.D. Anderson Cancer Center; and Professor of Bioengineering at Rice University. He is a founder of biomedical nano/micro-technology in biomedical applications, with more than 160 peer-reviewed journal articles, six books, more than 20 issued patents and about 30 more pending in the US and internationally. His career research and development portfolio totals over $50M.He served as Special Expert on Nanotechnology at the National Cancer Institute in 2003-2005. It seems that he is another good addition to ARWR's Board of Scientific Strategy.(BSS)<g> I think I will keep my target for ARWR at the $6 level.<g> bigcharts.marketwatch.com Bernard